Skip to main content
Delfa

← All assets

LMTM

7 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

7

Ongoing

0

Recruiting

0

Completed

4

Sites

378

Countries

20

Endpoints

67

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 67 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1
Phase 3
5
Not applicable
1

Trials by status

Completed
4
Terminated
2
Unknown
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Other (unclassified)
19
Neuroimaging
11
Safety / tolerability / PK
10
Global cognition
9
Function / daily living
8
Behavior / neuropsychiatric
3
Other clinical outcomes
3
Fluid / digital biomarkers
2
Caregiver / quality of life
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 18 of 67 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogOther

8

ADCS-Activities of Daily Living (ADCS-ADL)Function

6

Mini-Mental State Examination (MMSE)Cognition

3

Neuropsychiatric Inventory (NPI)Behavior

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

7 of 7

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT02245568Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

LMTM

Alzheimer’s disease, Frontotemporal dementia

Multiple dementia etiologiesPh 3Terminated135May 2017-results
NCT01689246Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

LMTM

Alzheimer’s disease

Alzheimer's diseasePh 3Completed121Nov 20151
NCT03446001Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

LMTM

Alzheimer’s disease

MCI due to ADPh 3Completed103Mar 2022-results
NCT01689233Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

LMTM

Alzheimer’s disease

Alzheimer's diseasePh 3Completed95May 2016-
NCT01626378Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

LMTM

Frontotemporal dementia

MMSE ≥20Ph 3Completed67Feb 20161
NCT01626391Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

LMTM

Alzheimer’s disease

Alzheimer's diseasePh 2Terminated12Mar 2013-results
NCT03539380TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

LMTM

Alzheimer’s disease

mild-to-moderate ADNot applicableUnknown0--

Showing 1-7 of 7 trials